antibiotics

an Open Access Journal by MDPI

IMPACT FACTOR 4.6

Indexed in: PubMed

CITESCORE 8.7

Antibiotic Adjuvants: An Approach to Overcoming Multi-Drug Resistance and Biofilm Infections

Guest Editors:

Dr. Luis G. Alves
Centro de Química Estrutural, Associação do Instituto Superior Técnico para a Investigação e Desenvolvimento, Lisbon, Portugal

Dr. Fatima Cerqueira

Deadline for manuscript submissions:
closed (15 August 2024)

Message from the Guest Editors

Dear Colleagues,

The incidence of infectious diseases caused by multi-drug-resistant pathogens has been increasing over the last few decades. These microorganisms are difficult to eradicate and are associated with worst outcomes than those caused by the respective susceptible strains. In addition, biofilm-associated microorganisms have shown a much higher resistance to antibiotics than planktonic microorganisms. While the emergence of multi-drug resistance has been associated with the misuse and abuse of antimicrobials, the number of available effective drugs is decreasing and novel compounds being introduced into the market are scarce. Therefore, current available antibiotic treatments often have limited or no efficacy against healthcare-associated infections (HCAIs), and novel therapeutic strategies need to be considered. This Special Issue aims to gather papers describing novel approaches to overcome infections caused by multi-drug-resistant microorganisms and/or those producing biofilms. In this context, papers on the description of antibiotic adjuvants are particularly welcome.

antibiotics

IMPACT FACTOR 4.6 | Indexed in: PubMed | CITESCORE 8.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
𝕏@antibioticsmdpi